Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Champions Oncology (NASDAQ:CSBR) has announced the full commercial launch of its radiopharmaceutical services platform, marking a significant expansion in its oncology research capabilities. The company has expanded its radioactive materials license to include 10 key isotopes and completed its radiochemistry infrastructure.
The platform combines advanced radiochemistry with Champions' extensive patient-derived xenograft (PDX) tumor models, enabling comprehensive evaluation of radiolabeled agents. The company has successfully screened over 30 PDX models in collaboration with pharmaceutical and biotech partners, offering integrated workflows for in vitro, ex-vivo biodistribution, and therapeutic efficacy studies.
Champions Oncology (NASDAQ:CSBR) ha annunciato il lancio commerciale completo della sua piattaforma di servizi radiofarmaceutici, segnando un'importante espansione delle sue capacità di ricerca oncologica. L'azienda ha ampliato la licenza per materiali radioattivi includendo 10 isotopi chiave e ha completato la sua infrastruttura di radiochimica.
La piattaforma combina una radiochimica avanzata con i vasti modelli tumorali xenotrapianti derivati da pazienti (PDX) di Champions, consentendo una valutazione completa degli agenti radiomarcati. L'azienda ha testato con successo oltre 30 modelli PDX in collaborazione con partner farmaceutici e biotecnologici, offrendo flussi di lavoro integrati per studi in vitro, biodistribuzione ex vivo e valutazione dell'efficacia terapeutica.
Champions Oncology (NASDAQ:CSBR) ha anunciado el lanzamiento comercial completo de su plataforma de servicios radiofarmacéuticos, marcando una expansión significativa en sus capacidades de investigación oncológica. La compañía ha ampliado su licencia para materiales radiactivos para incluir 10 isótopos clave y ha completado su infraestructura de radioquímica.
La plataforma combina radioquímica avanzada con los extensos modelos tumorales xenoinjertados derivados de pacientes (PDX) de Champions, permitiendo una evaluación integral de agentes radiomarcados. La empresa ha evaluado con éxito más de 30 modelos PDX en colaboración con socios farmacéuticos y biotecnológicos, ofreciendo flujos de trabajo integrados para estudios in vitro, biodistribución ex vivo y eficacia terapéutica.
Champions Oncology (NASDAQ:CSBR)가 방사성 의약품 서비스 플랫폼의 상업적 출시를 완료했다고 발표하며 종양학 연구 역량을 크게 확장했습니다. 회사는 방사성 물질 라이선스를 10가지 주요 동위원소로 확대하고 방사화학 인프라를 완성했습니다.
이 플랫폼은 첨단 방사화학과 Champions의 광범위한 환자 유래 이종이식(PDX) 종양 모델을 결합하여 방사성 표지제의 종합적인 평가를 가능하게 합니다. 회사는 제약 및 바이오테크 파트너와 협력하여 30개 이상의 PDX 모델을 성공적으로 스크리닝했으며, 시험관 내(in vitro), 생체 외(ex vivo) 생체 분포 및 치료 효능 연구를 위한 통합 워크플로우를 제공합니다.
Champions Oncology (NASDAQ:CSBR) a annoncé le lancement commercial complet de sa plateforme de services radiopharmaceutiques, marquant une expansion significative de ses capacités de recherche en oncologie. L'entreprise a étendu sa licence pour matériaux radioactifs afin d'inclure 10 isotopes clés et a finalisé son infrastructure de radiochimie.
La plateforme combine une radiochimie avancée avec les nombreux modèles tumoraux xénogreffes dérivés de patients (PDX) de Champions, permettant une évaluation complète des agents radiomarqués. L'entreprise a réussi à tester plus de 30 modèles PDX en collaboration avec des partenaires pharmaceutiques et biotechnologiques, offrant des flux de travail intégrés pour des études in vitro, de biodistribution ex vivo et d'efficacité thérapeutique.
Champions Oncology (NASDAQ:CSBR) hat die vollständige kommerzielle Einführung seiner radio-pharmazeutischen Dienstleistungsplattform bekannt gegeben, was eine bedeutende Erweiterung seiner onkologischen Forschungskapazitäten darstellt. Das Unternehmen hat seine Lizenz für radioaktive Materialien auf 10 wichtige Isotope ausgeweitet und seine Radiochemie-Infrastruktur fertiggestellt.
Die Plattform kombiniert fortschrittliche Radiochemie mit den umfangreichen patientenabgeleiteten Xenotransplantat (PDX) Tumormodellen von Champions, was eine umfassende Bewertung von radioaktiv markierten Wirkstoffen ermöglicht. Das Unternehmen hat erfolgreich über 30 PDX-Modelle in Zusammenarbeit mit Pharma- und Biotech-Partnern gescreent und bietet integrierte Arbeitsabläufe für in-vitro-, ex-vivo-Biodistributions- und Wirksamkeitsstudien.
- Expanded radioactive materials license to include 10 key isotopes for diverse study applications
- Successfully screened over 30 PDX models with pharmaceutical partners
- Integration of radiochemistry infrastructure with extensive PDX tumor bank creates unique market positioning
- Platform enables comprehensive evaluation of various therapeutic approaches including RLT, ARCs, and theranostics
- None.
Insights
Champions Oncology's radiopharmaceutical platform launch represents strategic expansion into high-growth precision oncology market with unique PDX model advantages.
Champions Oncology's full commercial launch of their radiopharmaceutical services platform marks a significant strategic expansion into one of oncology's fastest-growing therapeutic areas. The company has positioned itself at the intersection of two valuable technologies: radiopharmaceuticals and patient-derived xenograft (PDX) tumor models. This creates a differentiated market position that few competitors can match.
The expanded radioactive materials license covering ten key isotopes (Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89) is particularly significant as it enables Champions to support various therapeutic approaches - from established radioligand therapies using lutetium-177 to emerging alpha-emitter technologies utilizing actinium-225. This isotope diversity provides considerable flexibility in study design for pharmaceutical partners.
The successful screening of over 30 PDX models demonstrates early traction and validation of the platform. These screening collaborations with pharmaceutical and biotech partners suggest the company has already secured commercial interest ahead of the full launch, potentially accelerating revenue generation from this new service offering.
Champions' competitive advantage lies in combining radiochemistry capabilities with their established PDX platform. PDX models, which maintain the heterogeneity and microenvironment of human tumors, provide more translational relevance than traditional cell lines, potentially offering pharmaceutical clients enhanced predictive value for clinical outcomes. This addresses a critical need in radiopharmaceutical development where target expression, biodistribution, and therapeutic efficacy must be carefully evaluated in systems that closely mirror human disease.
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models
HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.
Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems.
"Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology," said Mike Ritchie, Chief Commercial Officer at Champions Oncology. "By combining advanced radiochemistry infrastructure with the world's most deeply characterized PDX bank, we're helping our clients generate meaningful, translational data that drives confident decision-making earlier in oncology drug development."
Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches.
"Our goal is to help biopharma partners answer critical questions faster, with data that reflects real tumor biology," continued Mike Ritchie, Chief Commercial Officer at Champions Oncology. "The integration of radionuclide workflows into our PDX platform provides a uniquely powerful preclinical toolset for evaluating biodistribution, tumor targeting, and therapeutic effect."
To learn more about Champions Oncology's radiopharmaceutical capabilities, visit:
https://www.championsoncology.com/radiopharmaceutical
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Contact
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
518 488 9026
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
What new capabilities has Champions Oncology (NASDAQ:CSBR) announced in July 2025?
Which isotopes are included in Champions Oncology's expanded license?
How does Champions Oncology's new radiopharmaceutical platform benefit drug developers?
What types of studies can be conducted on Champions Oncology's new platform?
